Ticagrelor monotherapy reduces bleeding complications with no increased risk of ischaemic events in patients with diabetes undergoing percutaneous coronary intervention (PCI)

In Phase IV TWILIGHT trial, ticagrelor monotherapy was associated with a 44% lower risk of bleeding over one year, with an absolute risk reduction of 3.1% compared to ticagrelor plus aspirin.